Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · Real-Time Price · USD
31.27
-0.02 (-0.06%)
At close: Jun 5, 2026, 4:00 PM EDT
31.26
-0.01 (-0.03%)
After-hours: Jun 5, 2026, 7:53 PM EDT

Catalyst Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, Catalyst Pharmaceuticals stock has a consensus rating of "Hold" and an average price target of $32.6. The average 1-year stock price forecast is 4.25% higher than the current stock price, while the lowest is $31.5 (+0.74%) and the highest is $36 (+15.13%).

Price Target: $32.6 (+4.25%)
Analyst Consensus: Hold
TargetLowAverageMedianHigh
Price$31.5$32.6$32$36
Change+0.74%+4.25%+2.33%+15.13%

Analyst Ratings

The average analyst rating for Catalyst Pharmaceuticals stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

RatingNov '25Jan '26Feb '26Mar '26Apr '26May '26
Strong Buy777771
Buy000000
Hold000005
Sell000000
Strong Sell000000
Total777776

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
H.C. Wainwright
H.C. Wainwright
Hold
Downgrades
$35$32
HoldDowngrades$35$32+0.74%May 28, 2026
Citi
Citi
Hold
Downgrades
$35$32
HoldDowngrades$35$32+0.74%May 8, 2026
Unknown Analyst
Robert W. Baird
No rating
Robert W. Baird
Hold
Downgrades
$32
HoldDowngrades$32+2.33%May 7, 2026
Oppenheimer
Oppenheimer
Hold
Downgrades
n/a
HoldDowngradesn/an/aMay 7, 2026
Stephens
Stephens
Hold
Downgrades
$32
HoldDowngrades$32+2.33%May 7, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
629.41M
from 588.99M
Increased by 6.86%
Revenue Next Year
701.61M
from 629.41M
Increased by 11.47%
EPS This Year
2.86
from 2.72
Increased by 5.12%
EPS Next Year
3.14
from 2.86
Increased by 9.67%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
140.83M214.20M398.20M491.73M588.99M629.41M
Revenue Growth
18.28%52.10%85.90%23.49%19.78%6.86%
Gross Profit
102.01M160.02M253.09M410.24M489.03M542.24M
Gross Margin
72.44%74.71%63.56%83.43%83.03%86.15%
Operating Income
52.39M101.84M86.81M195.12M257.78M273.31M
Net Income
39.48M83.08M71.41M163.89M214.33M223.23M
EPS
----2.722.86
EPS Growth
----23.08%5.12%
Forward PE
13.9714.9814.1315.3815.4810.94
Free Cash Flow
42.14M89.69M-219.49M201.64M171.34M221.00M
No. Analysts
-----2
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High632.2M
Avg629.4M
Low626.6M

Revenue Growth

Revenue Growth202620272028
High
7.3%
Avg
6.9%
Low
6.4%

EPS Forecast

EPS202620272028
High-
Avg2.86
Low-

EPS Growth

EPS Growth202620272028
High-
Avg
5.1%
Low-